Paiva B, Vidriales MB, Sempere A, Tarin F, Colado E, Benavente C, Cedena MT, Sanchez J, Caballero-Velazquez T, Cordon L, Garces JJ, Simoes C, Martinez-Cuadron D, Bernal T, Botella C, Grille S, Serrano J, Rodriguez-Medina C, Algarra L, Alonso-Dominguez JM, Amigo ML, Barrios M, Garcia-Boyero R, Colorado M, Perez-Oteyza J, Perez-Encinas M, Costilla-Barriga L, Sayas MJ, Perez O, Gonzalez-Diaz M, Perez-Simon JA, Martinez-Lopez J, Sossa C, Orfao A, San Miguel JF, Sanz MA, Montesinos P; PETHEMA (Programa para el Estudio de la Terapeutica en Hemopatias Malignas) cooperative study group. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia. 2021 Aug;35(8):2358-2370. doi: 10.1038/s41375-021-01126-3. Epub 2021 Feb 1. PubMed PMID: 33526859.
AÑO: 2021; IF: 12.883